Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
3,801
Views
18
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China

Mingjun Ruia School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China
,
Zhengyang Feia School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China
,
Yingcheng Wanga School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China
,
Xueke Zhanga School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China
,
Aixia Maa School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China
,
Haikui Sunc Innovent Biologics (Suzhou) Co., Ltd, Suzhou, Jiangsu, People’s Republic of China
&
Hongchao Lia School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of China;b Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 618-629 | Received 23 Dec 2021, Accepted 25 Apr 2022, Published online: 15 May 2022

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Mochong Liao & Shuo Kang. (2024) Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis. Expert Review of Pharmacoeconomics & Outcomes Research 24:1, pages 161-166.
Read now
Zhiwei Zheng, Gaofeng Zhu, Xueqiong Cao, Hongfu Cai & Huide Zhu. (2023) A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China. Expert Review of Clinical Pharmacology 16:3, pages 267-273.
Read now

Articles from other publishers (16)

Fuming Li, Yingyao Chen, Dunming Xiao, Shan Jiang & Yi Yang. (2024) Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective. Advances in Therapy.
Crossref
Changjin Wu, Wentan Li, Hongyu Tao, Xiyan Zhang, Yu Xin, Ruomeng Song, Kaige Wang, Ling Zuo, Yuanyi Cai, Huazhang Wu & Wen Hui. (2024) Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview. Critical Reviews in Oncology/Hematology 193, pages 104195.
Crossref
Mingjun Rui, Yingcheng Wang, Yunfei Li & Zhengyang Fei. (2023) Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis. BioDrugs 38:1, pages 157-170.
Crossref
Yunlin Jiang, Mingye Zhao, Ruolin Liu & Xueping Zheng. (2023) Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: A cost-effectiveness analysis to inform drug pricing. Medicine 102:50, pages e36387.
Crossref
Yijin Qiu, Jingkai Zha, Aixia Ma & Ting Zhou. (2023) Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology 174, pages 175-181.
Crossref
Taihang Shao, Mingye Zhao, Leyi Liang & Wenxi Tang. (2023) Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing. BioDrugs 37:3, pages 421-432.
Crossref
Xi Chen, Mingye Zhao & Lei Tian. (2023) Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis. Frontiers in Pharmacology 14.
Crossref
Mingye Zhao, Taihang Shao, Zhuoyuan Chi & Wenxi Tang. (2023) Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model. Frontiers in Public Health 11.
Crossref
Gengwei Huo, Wenjie Liu, Shuo Kang & Peng Chen. (2023) Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis. Frontiers in Pharmacology 14.
Crossref
Hongbin Dai, Wenyue Wang, Xin Fan & Yongfa Chen. (2023) Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China. Frontiers in Medicine 10.
Crossref
Lulu Liu, Lei Wang, Li Chen, Yiling Ding, Qilin Zhang & Yamin Shu. (2023) Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma. Frontiers in Immunology 14.
Crossref
Maojin You, Yufan Huang, Zhongjie Cai, Qingfeng Wu, Wei Zhu, Ying He & Ruijia Chen. (2022) Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma. Frontiers in Oncology 12.
Crossref
Ping Chen, Yinfeng Li, Xiaomei Jing, Jing Chen, Shimei Chen & Qing Yang. (2022) Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC. Lung Cancer 174, pages 157-164.
Crossref
Zhuo-Miao Ye, Zhe Xu, Fan-Yuan Zeng, Zi-Qing Tang & Qin Zhou. (2022) Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer. Frontiers in Pharmacology 13.
Crossref
Wei Li & Li Wan. (2022) Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China. Frontiers in Public Health 10.
Crossref
Taihang Shao, Yinan Ren, Mingye Zhao & Wenxi Tang. (2022) Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China. Frontiers in Public Health 10.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.